WO1991002252A1 - Antigenes specifiques aux plaques d'atherosclerose, anticorps diriges contre ces antigenes et utilisations de ces antigenes et de ces anticorps - Google Patents

Antigenes specifiques aux plaques d'atherosclerose, anticorps diriges contre ces antigenes et utilisations de ces antigenes et de ces anticorps Download PDF

Info

Publication number
WO1991002252A1
WO1991002252A1 PCT/US1990/004272 US9004272W WO9102252A1 WO 1991002252 A1 WO1991002252 A1 WO 1991002252A1 US 9004272 W US9004272 W US 9004272W WO 9102252 A1 WO9102252 A1 WO 9102252A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antigen
reagent
enzyme
atherosclerotic plaque
Prior art date
Application number
PCT/US1990/004272
Other languages
English (en)
Inventor
Emanuel Calenoff
Original Assignee
Vasocor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasocor filed Critical Vasocor
Publication of WO1991002252A1 publication Critical patent/WO1991002252A1/fr
Priority to US08/386,221 priority Critical patent/US6025477A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Abstract

L'invention concerne des antigènes purifiés qui sont indicateurs de la présence de plaques d'athérosclérose. On a découvert que différentes concentrations de ces antigènes coïncident avec la progression de l'athérosclérose. L'invention concerne également différrentes lignées de cellules d'hybridomes, qui produisent des anticorps monoclonaux dirigés contre les antigènes associés à l'athérosclérose, et une lignée de cellules d'hybridomes qui produit des anticorps monoclonaux dirigés contre l'antigène associé à l'état normal des artères et non à la plaque. L'antigène de la plaque d'athérosclérose et les anticorps monoclonaux fabriqués à partir de cet antigène sont utilisés dans divers procédés de détection d'un échantillon biologique dans un antigène présent dans la plaque d'athérosclérose et indicateur de la présence de plaque d'athérosclérose.
PCT/US1990/004272 1986-03-31 1990-07-31 Antigenes specifiques aux plaques d'atherosclerose, anticorps diriges contre ces antigenes et utilisations de ces antigenes et de ces anticorps WO1991002252A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/386,221 US6025477A (en) 1986-03-31 1995-02-09 Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38812989A 1989-07-31 1989-07-31
US388,129 1989-07-31

Publications (1)

Publication Number Publication Date
WO1991002252A1 true WO1991002252A1 (fr) 1991-02-21

Family

ID=23532828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/004272 WO1991002252A1 (fr) 1986-03-31 1990-07-31 Antigenes specifiques aux plaques d'atherosclerose, anticorps diriges contre ces antigenes et utilisations de ces antigenes et de ces anticorps

Country Status (5)

Country Link
EP (1) EP0485476A4 (fr)
JP (1) JPH05500307A (fr)
AU (1) AU6164290A (fr)
CA (1) CA2060663A1 (fr)
WO (1) WO1991002252A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021581A1 (fr) * 1996-11-08 1998-05-22 The Regents Of The University Of California Procedes et reactifs destines a l'imagerie non invasive d'une plaque d'atherosclerose
US6375925B1 (en) * 1996-11-08 2002-04-23 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
US7811570B2 (en) 1992-04-07 2010-10-12 Immunomedics, Inc. Method of affecting a function of or ablating a non-malignant cell
US8129123B2 (en) 2004-10-05 2012-03-06 The Regents Of The University Of California Methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein B ratios

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196324A (en) * 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628027A (en) * 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
US4912030A (en) * 1985-01-15 1990-03-27 Institute Of Cancer Research Viral isolates and their use in diagnosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293524A1 (fr) * 1987-06-02 1988-12-07 Vasocor Immunoessai de plaque athérosclérotique
CA1320461C (fr) * 1988-02-04 1993-07-20 Tatsuya Takano Anticorps monoclonal capable de reconnaitre l'arterisoclerose humaine et methode pour le preparer
CA1340977C (fr) * 1988-11-15 2000-04-25 Monty Krieger Recepteur proteique capteur, ainsi que son anticorps

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628027A (en) * 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
US4912030A (en) * 1985-01-15 1990-03-27 Institute Of Cancer Research Viral isolates and their use in diagnosis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Acta. path. microbiol. immunol. Scand. Sect. C. Volume 92, 1984, VEDELER et al, "In Situ Characterization of the foam cells in early human Artherosclerotic Lesions", pages 133-137, see entire document. *
Atherosclerosis, Volume 6, No. 2, issued March, 1986, JONASSAN et al, "Regional Accumulations of T cells, macrophages, and smooth muscle cells in the Human Atherosclerotic Plague", pages 131-138, see entire document. *
Biological Abstracts, Vol. 73, No. 11, issued 01 June 1982, SHANMUGASUNDARAM, et al, "Studies on intestinal and Muscle Protein bound Carbohydrate Components in Experimental Hyper cholesterolemia: effect of Annapavalasind Hooram: an indigenous drug formulation". see page 8129, column 1, Abstract No. 77926, J. Indian Inst. Sc Sect. C Biol. Sc 1, 63(4), 1-12, 1981. *
CHEMICAL ABSTRACTS, Vol 98, 1983 (Columbus, Ohio, USA), SOBANIEC et al, "Histological histochemical, and ultrastructure examination of the rat aorta at the early period of experimental atherosclerosis" see page 470, column 2, Abstract No. 177118, Rocz. Akad. Med. Im. Juliana Marchlewskicgo Bialymstoku, 1982, 27, 167-78 (Po 1). *
Diagnostic Horizons, Volume 2, No. 1, issued February 1978, (Maryland, US) A. VOLLER, "The Enzyme Linked Immunosorbent Assay (ELISA)", pages 1-7, see entire document. *
See also references of EP0485476A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811570B2 (en) 1992-04-07 2010-10-12 Immunomedics, Inc. Method of affecting a function of or ablating a non-malignant cell
WO1998021581A1 (fr) * 1996-11-08 1998-05-22 The Regents Of The University Of California Procedes et reactifs destines a l'imagerie non invasive d'une plaque d'atherosclerose
US6375925B1 (en) * 1996-11-08 2002-04-23 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
US8129123B2 (en) 2004-10-05 2012-03-06 The Regents Of The University Of California Methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein B ratios
US9075050B2 (en) 2004-10-05 2015-07-07 The Regents Of The University Of California Methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein B ratios

Also Published As

Publication number Publication date
EP0485476A1 (fr) 1992-05-20
AU6164290A (en) 1991-03-11
EP0485476A4 (en) 1993-03-03
JPH05500307A (ja) 1993-01-28
CA2060663A1 (fr) 1991-02-01

Similar Documents

Publication Publication Date Title
US6025477A (en) Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
US4900662A (en) CK-MM myocardial infarction immunoassay
US4677057A (en) Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins
JP4859904B2 (ja) 平滑筋増殖抑制組成物、動脈硬化症予防及び治療組成物及び血管再建術後の再狭窄予防及び治療組成物
CA1338706C (fr) Anticorps monoclonaux anti-cancer du sein chez la femme; leur utilisation pour visualiser ce type de cancer
JP2664913B2 (ja) フィブリン特異的抗体および前記抗体のスクリーン方法
JP3419772B2 (ja) フィブリン結合ドメインポリペプチド及びその使用，並びにその製造方法
JP2505218B2 (ja) アポリポタンパクａ―１に対して特異性を有するモノクロ―ナル抗体又はそのパラト―プ含有ポリペプチド部分並びにそれを使用する診断装置
US6132976A (en) Immunoassays for the measurement of collagen denaturation and cleavage in cartilage
AU639282B2 (en) Monoclonal antibodies reactive with a human atheroma associated antigen
US5382515A (en) Creative kinase-MB immunoassay for myocardial infarction and reagents
US5866690A (en) Detection of malignant tumor cells
Minta The role of sialic acid in the functional activity and the hepatic clearance of C1-INH.
Healy et al. Immunocytochemical localization of endopeptidase 24.15 in rat brain
US4778752A (en) Receptors specific for hapten-modified self proteins
US5382522A (en) Immunoassay for creatine kinase-MB and creatine kinase-BB isoforms and reagents
Mort et al. Immunofluorescent localization of cathepsins B and D in human fibroblasts.
US5955584A (en) Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
EP0267690A1 (fr) Titrage d'un immun-complexe
US5811248A (en) Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
Sanchez et al. Cholesterol and apolipoprotein D in gross cystic disease of the breast
US7094580B2 (en) Methods for producing pure perlecan and other heparan sulfate proteoglycans
WO1991002252A1 (fr) Antigenes specifiques aux plaques d'atherosclerose, anticorps diriges contre ces antigenes et utilisations de ces antigenes et de ces anticorps
EP0387027A2 (fr) Méthodes et réactifs pour le diagnostic de l'endométriose
Jonsson et al. Demonstration of immunoreactive sites on cartilage after in vivo administration of biotinylated anti-type II collagen antibodies.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2060663

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1990912266

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990912266

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1990912266

Country of ref document: EP